Skip to main content
Erschienen in: Journal of Translational Medicine 1/2010

Open Access 01.11.2010 | Poster presentation

BioRePortAP, an electronic clinical record coupled with a database: an example of its use in a single centre

verfasst von: R Campanilho-Marques, J Polido Pereira, A M Rodrigues, F Ramos, M J Saavedra, M Costa, J A Pereira da Silva, H Canhão, J E Fonseca

Erschienen in: Journal of Translational Medicine | Sonderheft 1/2010

insite
INHALT
download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Aims

To evaluate the efficacy and safety of the treatment of psoriatic arthritis (PsA) patients with tumor necrosis factor (TNF) antagonists in the Rheumatology Dept. of Hospital de Santa Maria using the BioRePortAP.

Methods

The Portuguese Society of Rheumatology (SPR) developed an electronic medical chart coupled with a database for the follow up of PsA patients, the BioRePortAP, which was launched in May 2009. This evaluation was based on all the PsA patients that were on active treatment with TNF antagonists in September 2009 and were registered in the BioRePortAP. All the previous data on these patients were introduced in BioRePortAP using the prospective paper based follow up protocol that this Dept. was using since 1999. Only patients with more than 9 months of treatment were analyzed.

Results

Forty-two patients with PsA, actively treated with anti-TNF agents in September 2009, for at least 9 months, were analyzed in BioRePortAP. Twenty-three patients were male (55%) and nineteen were female (45%). The average age of these patients was 49.8±10.9 years old, the average disease duration was of 10.7±5.6 years and the mean duration of biological therapy was of 37.8±27.8 months. For the 81% of patients with peripheral joint disease there was a mean reduction of more than 80% in the swollen and tender joint counts, and almost 50% in the HAQ value. In the 19% of the patients with axial involvement the reduction of BASDAI and BASFI was not statistically significant. On top of that, PASI score suffered a reduction of 64%. Fourteen patients (33.3%) had to switch their TNF antagonist treatment. 58.8% of the switches were due to adverse effects and 41.2% due to therapy failure. Regarding the 56 adverse reactions registered, only one was a severe reaction. The remaining adverse reactions were not severe and 67% of them were due to infections.

Discussion

The results of this first report of the use of the BioRePortAP in clinical practice confirm the efficacy and safety of TNF antagonist treatment in PsA. The results shown here elucidate the potential applications of BioRePortAP as a tool for efficacy and safety assessment of PsA patients treated with biotechnological drugs.
Open AccessThis article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
insite
INHALT
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
BioRePortAP, an electronic clinical record coupled with a database: an example of its use in a single centre
verfasst von
R Campanilho-Marques
J Polido Pereira
A M Rodrigues
F Ramos
M J Saavedra
M Costa
J A Pereira da Silva
H Canhão
J E Fonseca
Publikationsdatum
01.11.2010
Verlag
BioMed Central
Erschienen in
Journal of Translational Medicine / Ausgabe Sonderheft 1/2010
Elektronische ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-8-S1-P63

Weitere Artikel der Sonderheft 1/2010

Journal of Translational Medicine 1/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.